News

A team of researchers from the Netherlands Institute for Neuroscience, one of the causes is the spontaneous back-and-forth movement of the eye is pendular nystagmus. The researchers have demonstrated that the nucleus of the optic tract might be the source of the problem.

Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.

Staging AMD accurately and identifying clinical features that are linked with disease progression are key.

The plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.

Eye symptoms such as dry, itchy, red, painful, watery, and gritty eyes can happen before the smoke is even noticeable.

Theodore Leng, MD, sat down with David Hutton of Ophthalmology Times®, to discuss his ASRS presentation on how the real-world use of faricimab.

Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of August 6, 2023.

A team of researchers at Anglia Ruskin University are harnessing nanotechnology to help tackle a common cause of sight loss.

According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.

Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.

Kerrie Brady, Chief Executive Officer and President of OcuTerra Therapeutics shared updates from the company including the development of OTT166 at the 2023 ASRS annual meeting.

An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.

An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.

An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.

At the 2023 ASRS annual meeting, Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901.

An experienced dermatologist blinded to clinical data performed the NVC using a videocapillaroscope VideoCap 3.0 (DSMedica) at 200× magnification in the study.

According to Johns Hopkins Medicine, the gift brings T. Boone Pickens’ total donations to Wilmer to more than $28 million.

At the 2023 ASRS annual meeting, Aleksandra Rachiskaya, MD, spoke about time to fluid control with faricimab arms complete compared to aflibercept in recent studies.

David Lally, MD, spoke with our team about the ZETA-1 phase 2 trial efficacy results for APX3330, a novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy at the 2023 ASRS annual meeting.

David Lally, MD, spoke with our team about the ZETA-1 phase 2 trial efficacy results for APX3330, a novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy at the 2023 ASRS annual meeting.

An experienced dermatologist blinded to clinical data performed the NVC using a videocapillaroscope VideoCap 3.0 (DSMedica) at 200× magnification in the study.

Surgeons can refine their workflow, partner with an optometrist.

Oculis Holding AG announced, if approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

Intergalactic Therapeutics, based in Cambridge, MA, announced its closing after less than 2 years since the company's launch in 2021.